[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:precursor-b-cell-acute-lymphoblastic-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":36,"states":37},"Precursor B-cell acute lymphoblastic leukemia",4,1,[8,15,23,30],{"nct_id":9,"title":10,"phases":11,"status":12,"updated_at":13,"content_modified":14},"NCT05865301","Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy",[],"RECRUITING","2026-08-26T02:18:59.761994Z","2026-05-13T02:55:06.390506Z",{"nct_id":16,"title":17,"phases":18,"status":20,"updated_at":21,"content_modified":22},"NCT07134088","A Study of Subcutaneous Blinatumomab in Children With R\u002FR and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia",[19],"Phase 1\u002FPhase 2","ACTIVE_NOT_RECRUITING","2026-08-03T03:26:30.254593Z","2026-05-05T02:43:29.583901Z",{"nct_id":24,"title":25,"phases":26,"status":20,"updated_at":28,"content_modified":29},"NCT04994717","Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia",[27],"Phase 3","2026-08-03T02:38:08.863295Z","2026-05-05T02:43:28.347861Z",{"nct_id":31,"title":32,"phases":33,"status":20,"updated_at":34,"content_modified":35},"NCT04521231","A Study of Subcutaneous Blinatumomab Administration in Participants With R\u002FR and MRD+ B-ALL",[19],"2026-08-03T03:54:23.387833Z","2026-05-05T02:43:27.134795Z",[],[38,41,45,48],{"state":39,"count":5,"slug":40},"California","california",{"state":42,"count":43,"slug":44},"Pennsylvania",3,"pennsylvania",{"state":46,"count":43,"slug":47},"Texas","texas",{"state":49,"count":43,"slug":50},"Washington","washington"]